ArticleClinical pharmacokinetics2026
Population Pharmacokinetics of Total and Protein-Unbound Prednisolone in Children with Immune-Mediated and Systemic Inflammatory Diseases.
Article in Clinical pharmacokinetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveHigh-dose systemic prednisolone is the mainstay treatment of children with various (auto)immune diseases. The standard empirical dosing regimen with dosages up to 2 mg/kg/day is generally adequate for immune suppression, though often accompanied by substantial adverse effects in the majority of patients. Pharmacokinetic (PK) variability may be an important determinant for both efficacy and toxicity but has only limitedly been investigated in children. This research aimed to characterise the population pharmacokinetics and determinants of variability of protein-bound and unbound prednisolone in children with (auto)immune diseases.
methodsPatients received ≥ 0.5 mg/kg systemic prednisolone for either an autoimmune disease or as part of allogeneic haematopoietic cell transplantation (HCT). A priori allometric scaling was implemented, normalised to a body weight (BW) of 70 kg.
resultsThe study population consisted of 60 children with a median (range) age of 10 (0.2-19) years and a BW of 36.5 (5.0-109) kg. A total of 305 serum samples from 68 PK occasions were measured for total and protein-unbound prednisolone concentrations. The PK data were best described by a two-compartment model, accounting for both the linear and saturable binding of prednisolone to albumin and corticosteroid binding globulin (CBG), respectively, and the circadian rhythm of CBG. The population estimates (95% confidence interval [CI]) for the binding affinity of prednisolone to albumin was 200 µM (164-253) and to CBG was 0.048 µM (0.043-0.053). The population estimate for clearance (95% CI) was 155 L/h (137-182). Patients with prednisolone as prophylaxis following HCT had a 10% higher clearance compared with patients treated for graft-versus-host disease or an autoimmune disease.
conclusionThis population PK model provides valuable insights into PK variability of prednisolone and can be used to address the clinical implications of BW-based dosing of prednisolone in children with immune-mediated and inflammatory diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.